| Dr Elizabeth M Rau, MD | |
|
700 W Ironwood Dr Ste 320, Coeur D Alene, ID 83814 | |
| (208) 625-5250 | |
| (208) 625-5251 |
| Full Name | Dr Elizabeth M Rau |
|---|---|
| Gender | Female |
| Speciality | Interventional Cardiology |
| Experience | 13 Years |
| Location | 700 W Ironwood Dr Ste 320, Coeur D Alene, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538455878 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kootenai Health | Coeur d'alene, ID | Hospital |
| Gritman Medical Center | Moscow, ID | Hospital |
| St Joseph Regional Medical Center | Lewiston, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kootenai Health Inc | 1355792276 | 291 |
| Kootenai Health, Inc. | 4789641598 | 331 |
News Archive
In 2010, the American Society of Anesthesiologists® (ASA®) introduced a mannequin-based simulation program to satisfy the American Board of Anesthesiology requirements for Maintenance of Certification in Anesthesiology (MOCA).
Drugs based on engineered proteins represent a new frontier for pharmaceutical makers. Even after they discover a protein that may form the basis of the next wonder drug, however, they have to confront a long-standing problem: how to produce large quantities of the protein in a highly pure state.
Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually curable with traditional therapies like surgery, radiation, and chemotherapy.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.
› Verified 1 days ago
| Entity Name | Kootenai Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235288655 PECOS PAC ID: 4789641598 Enrollment ID: O20041214000230 |
News Archive
In 2010, the American Society of Anesthesiologists® (ASA®) introduced a mannequin-based simulation program to satisfy the American Board of Anesthesiology requirements for Maintenance of Certification in Anesthesiology (MOCA).
Drugs based on engineered proteins represent a new frontier for pharmaceutical makers. Even after they discover a protein that may form the basis of the next wonder drug, however, they have to confront a long-standing problem: how to produce large quantities of the protein in a highly pure state.
Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually curable with traditional therapies like surgery, radiation, and chemotherapy.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.
› Verified 1 days ago
| Entity Name | St Joseph Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205368404 PECOS PAC ID: 8325325806 Enrollment ID: O20170606002496 |
News Archive
In 2010, the American Society of Anesthesiologists® (ASA®) introduced a mannequin-based simulation program to satisfy the American Board of Anesthesiology requirements for Maintenance of Certification in Anesthesiology (MOCA).
Drugs based on engineered proteins represent a new frontier for pharmaceutical makers. Even after they discover a protein that may form the basis of the next wonder drug, however, they have to confront a long-standing problem: how to produce large quantities of the protein in a highly pure state.
Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually curable with traditional therapies like surgery, radiation, and chemotherapy.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.
› Verified 1 days ago
| Entity Name | Kootenai Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174661151 PECOS PAC ID: 1355792276 Enrollment ID: O20240111003252 |
News Archive
In 2010, the American Society of Anesthesiologists® (ASA®) introduced a mannequin-based simulation program to satisfy the American Board of Anesthesiology requirements for Maintenance of Certification in Anesthesiology (MOCA).
Drugs based on engineered proteins represent a new frontier for pharmaceutical makers. Even after they discover a protein that may form the basis of the next wonder drug, however, they have to confront a long-standing problem: how to produce large quantities of the protein in a highly pure state.
Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually curable with traditional therapies like surgery, radiation, and chemotherapy.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elizabeth M Rau, MD 2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 Ph: (208) 625-5059 | Dr Elizabeth M Rau, MD 700 W Ironwood Dr Ste 320, Coeur D Alene, ID 83814 Ph: (208) 625-5250 |
News Archive
In 2010, the American Society of Anesthesiologists® (ASA®) introduced a mannequin-based simulation program to satisfy the American Board of Anesthesiology requirements for Maintenance of Certification in Anesthesiology (MOCA).
Drugs based on engineered proteins represent a new frontier for pharmaceutical makers. Even after they discover a protein that may form the basis of the next wonder drug, however, they have to confront a long-standing problem: how to produce large quantities of the protein in a highly pure state.
Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually curable with traditional therapies like surgery, radiation, and chemotherapy.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.
› Verified 1 days ago
Diana Johns, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2248 W Rosebud Ln, Coeur D Alene, ID 83814 Phone: 907-687-6248 | |
Marc Olav Granrud, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-6900 Fax: 208-625-6710 | |
Kevin Nathaniel Brown, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-6900 Fax: 208-625-6910 | |
Edward J Macinerney, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 W Ironwood Dr Ste 320, Coeur D Alene, ID 83814 Phone: 208-625-5250 Fax: 208-625-5251 | |
Dr. Amanda Rose Liggett, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 W Ironwood Dr Ste 378, Coeur D Alene, ID 83814 Phone: 208-625-3555 Fax: 208-765-1494 | |
Dr. Robert Scoggins, M.D., PH.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 W Ironwood Dr Ste 378, Coeur D Alene, ID 83814 Phone: 208-765-1252 Fax: 208-765-1494 | |
Dr. Sean Tristan Lawrence Cook, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2120 W Ironwood Center Dr, Coeur D Alene, ID 83814 Phone: 208-625-6944 Fax: 208-625-6945 |